The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: Where is the clinically relevant hotspot for prostate cancer?

Takashi Matsumoto; Masaki Shiota

doi:10.21037/tau-20-866

The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: Where is the clinically relevant hotspot for prostate cancer?

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

本文言語	英語
ページ（範囲）	2289-2291
ページ数	3
ジャーナル	Translational Andrology and Urology
巻	9
号	5
DOI	https://doi.org/10.21037/tau-20-866
出版ステータス	出版済み - 10月 2020

!!!All Science Journal Classification (ASJC) codes

生殖医学
泌尿器学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.21037/tau-20-866

他のファイルとリンク

引用スタイル

@article{cb9f0cad15da4eaba679b2c7760d7528,

title = "The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: Where is the clinically relevant hotspot for prostate cancer?",

author = "Takashi Matsumoto and Masaki Shiota",

year = "2020",

month = oct,

doi = "10.21037/tau-20-866",

language = "English",

volume = "9",

pages = "2289--2291",

journal = "Translational Andrology and Urology",

issn = "2223-4683",

publisher = "AME Publishing Company",

number = "5",

}

TY - JOUR

T1 - The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers

T2 - Where is the clinically relevant hotspot for prostate cancer?

AU - Matsumoto, Takashi

AU - Shiota, Masaki

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85096196045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096196045&partnerID=8YFLogxK

U2 - 10.21037/tau-20-866

DO - 10.21037/tau-20-866

M3 - Comment/debate

AN - SCOPUS:85096196045

SN - 2223-4683

VL - 9

SP - 2289

EP - 2291

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

IS - 5

ER -